Outlook Therapeutics reports FY2022 net loss $66.1M; raises ~$55M; PDUFA date Aug 29, 2023

Outlook Therapeutics, Inc.

Net loss $66.1M ($0.31/sh) for FY2022 vs $53.2M ($0.35/sh) in FY2021.
Cash and equivalents $17.4M at Sept 30, 2022; subsequent financings raised ~$55M gross.
FDA accepted BLA for ONS-5010; PDUFA goal date set for August 29, 2023.
Entered strategic commercialization agreement with AmerisourceBergen for 3PL and services.
Appointed Julia Haller, MD to the Board of Directors.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Outlook Therapeutics, Inc. reported financial results for fiscal year ended September 30, 2022.

Period: fiscal year ended September 30, 2022
Result: reported results

Exact text from the filing

On December 29, 2022, Outlook Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for its fourth fiscal quarter and year ended September 30, 2022.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Outlook Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-130714

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.